| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 4835 | 2016 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 769 | 2018 |
| An update on larynx cancer CE Steuer, M El‐Deiry, JR Parks, KA Higgins, NF Saba CA: a cancer journal for clinicians 67 (1), 31-50, 2017 | 740 | 2017 |
| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542-1549, 2017 | 683 | 2017 |
| Sickle blood contains tissue factor–positive microparticles derived from endothelial cells and monocytes AS Shet, O Aras, K Gupta, MJ Hass, DJ Rausch, N Saba, L Koopmeiners, ... Blood 102 (7), 2678-2683, 2003 | 660 | 2003 |
| Head and neck cancer MD Mody, JW Rocco, SS Yom, RI Haddad, NF Saba The Lancet 398 (10318), 2289-2299, 2021 | 508 | 2021 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 422 | 2017 |
| Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973‐2007 surveillance, epidemiology, and end results data CL Ellington, M Goodman, SA Kono, W Grist, T Wadsworth, AY Chen, ... Cancer 118 (18), 4444-4451, 2012 | 364 | 2012 |
| Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial LL Siu, C Even, R Mesía, E Remenar, A Daste, JP Delord, J Krauss, ... JAMA oncology 5 (2), 195-203, 2019 | 281 | 2019 |
| Management of locally recurrent nasopharyngeal carcinoma AWM Lee, WT Ng, JYW Chan, J Corry, A Mäkitie, WM Mendenhall, ... Cancer treatment reviews 79, 101890, 2019 | 278 | 2019 |
| Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer … RL Ferris, Y Flamand, GS Weinstein, S Li, H Quon, R Mehra, JJ Garcia, ... Journal of clinical oncology 40 (2), 138-149, 2022 | 260 | 2022 |
| Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer CS Eberhardt, HT Kissick, MR Patel, MA Cardenas, N Prokhnevska, ... Nature 597 (7875), 279-284, 2021 | 227 | 2021 |
| Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009 B Ansa, M Goodman, K Ward, SA Kono, TK Owonikoko, K Higgins, ... Cancer 119 (14), 2602-2610, 2013 | 224 | 2013 |
| Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review P Strojan, JB Vermorken, JJ Beitler, NF Saba, M Haigentz Jr, P Bossi, ... Head & neck 38 (S1), E2151-E2158, 2016 | 202 | 2016 |
| Defining HPV-specific B cell responses in patients with head and neck cancer A Wieland, MR Patel, MA Cardenas, CS Eberhardt, WH Hudson, ... Nature 597 (7875), 274-278, 2021 | 171 | 2021 |
| Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results … NF Saba, M Goodman, K Ward, C Flowers, S Ramalingam, T Owonikoko, ... Oncology 81 (1), 12-20, 2011 | 158 | 2011 |
| Nasal juvenile angiofibroma: Current perspectives with emphasis on management F López, A Triantafyllou, CH Snyderman, JL Hunt, C Suárez, VJ Lund, ... Head & neck 39 (5), 1033-1045, 2017 | 155 | 2017 |
| Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use RL Ferris, L Licitra, J Fayette, C Even, G Blumenschein Jr, KJ Harrington, ... Clinical Cancer Research 25 (17), 5221-5230, 2019 | 151 | 2019 |
| Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations AL Ho, I Brana, R Haddad, J Bauman, K Bible, S Oosting, DJ Wong, ... Journal of Clinical Oncology 39 (17), 1856-1864, 2021 | 147 | 2021 |
| ACR Appropriateness Criteria® retreatment of recurrent head and neck cancer after prior definitive radiation: Expert panel on radiation oncology–head and neck cancer MW McDonald, J Lawson, MK Garg, H Quon, JA Ridge, N Saba, ... International Journal of Radiation Oncology* Biology* Physics 80 (5), 1292-1298, 2011 | 130 | 2011 |
